Alsoudi Amer F, Wai Karen M, Koo Euna, Koo Eubee, Mruthyunjaya Prithvi, Rahimy Ehsan
Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA.
Horngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.
Sci Rep. 2025 Jul 12;15(1):25215. doi: 10.1038/s41598-025-08971-7.
Elucidating the outcomes of patients using continuous glucose monitoring (continuous glucose monitoring) in day-to-day clinical practice could help expand optimal practice guidelines in prevention and mitigation of diabetic retinopathy (DR). Retrospective cohort study. Subjects, Participants, and/or Controls: 13,302 patients with NPDR initiated on continuous glucose monitoring, compared with 179,079 patients with NPDR not initiated on continuous glucose monitoring before propensity score matching (propensity score matching) at one year. TriNetX (Cambridge, MA, USA), was used to identify patients diagnosed with NPDR stratified by initiation of continuous glucose monitoring or not with at least six months of follow-up. propensity score matching controlled for baseline demographics and medical comorbidities. After propensity score matching, 12,730 patients were subsequently analyzed in each cohort. Use of continuous glucose monitoring was associated with lower risk of vision threatening complications (DME: hazards ratio [HR], 0.87, 95% CI, 0.82-0.93; P < .001; PDR: HR, 0.74, 95% CI, 0.66-0.82; P < .001; VH: HR, 0.55, 95% CI, 0.47-0.66; P < .001; TRD: HR, 0.42, 95% CI, 0.27-0.68; P = .027), and need for ocular intervention (anti-VEGF injection: HR, 0.72, 95% CI, 0.65-0.80; P < .001; PRP: HR, 0.53, 95% CI, 0.44-0.64; P < .001; PPV: HR, 0.37, 95% CI, 0.26-0.51; P < .001) among patients with NPDR when compared with matched patients not using continuous glucose monitoring at 1 year. Similar associations at two years were found. continuous glucose monitoring use in patients with NPDR without prior ocular therapy was associated with lower risk of progression to vision threatening complications as well as need for ocular intervention at one year and two years, highlighting that glycemic variability and time in range are important factors influencing the risk of complications from diabetic eye disease.
在日常临床实践中阐明使用持续葡萄糖监测(动态血糖监测)的患者的预后,有助于扩展预防和减轻糖尿病视网膜病变(DR)的最佳实践指南。回顾性队列研究。研究对象、参与者和/或对照:13302例开始使用动态血糖监测的非增殖性糖尿病视网膜病变(NPDR)患者,与179079例在倾向得分匹配(倾向得分匹配)前一年未开始使用动态血糖监测的NPDR患者进行比较。使用TriNetX(美国马萨诸塞州剑桥市)来识别诊断为NPDR的患者,根据是否开始使用动态血糖监测进行分层,并进行至少六个月的随访。倾向得分匹配控制了基线人口统计学和医疗合并症。倾向得分匹配后,每个队列随后分析了12730例患者。与1年时未使用动态血糖监测的匹配患者相比,使用动态血糖监测与NPDR患者视力威胁性并发症(糖尿病性黄斑水肿:风险比[HR],0.87,95%置信区间,0.82 - 0.93;P < 0.001;增殖性糖尿病视网膜病变:HR,0.74,95%置信区间,0.66 - 0.82;P < 0.001;玻璃体出血:HR,0.55,95%置信区间,0.47 - 0.66;P < 0.001;牵引性视网膜脱离:HR,0.42,95%置信区间,0.27 - 0.68;P = 0.027)以及眼部干预需求(抗血管内皮生长因子注射:HR,0.72,95%置信区间,0.65 - 0.80;P < 0.001;全视网膜光凝:HR,0.53,95%置信区间,0.44 - 0.64;P < 0.001;玻璃体切割术:HR,0.37,95%置信区间,0.26 - 0.51;P < 0.001)的风险较低相关。在两年时发现了类似的关联。在未接受过眼部治疗的NPDR患者中使用动态血糖监测与在一年和两年时进展为视力威胁性并发症以及眼部干预需求的风险较低相关,这突出表明血糖变异性和血糖达标时间是影响糖尿病眼病并发症风险的重要因素。